240 related articles for article (PubMed ID: 28879638)
1. Impact of Etoposide on BRCA1 Expression in Various Breast Cancer Cell Lines.
Zhang X; Hofmann S; Harbeck N; Jeschke U; Sixou S
Drugs R D; 2017 Dec; 17(4):569-583. PubMed ID: 28879638
[TBL] [Abstract][Full Text] [Related]
2. Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.
Alshareeda AT; Negm OH; Aleskandarany MA; Green AR; Nolan C; TigHhe PJ; Madhusudan S; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Aug; 159(1):41-53. PubMed ID: 27464795
[TBL] [Abstract][Full Text] [Related]
3. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
Aleskandarany M; Caracappa D; Nolan CC; Macmillan RD; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2015 Feb; 150(1):81-90. PubMed ID: 25690937
[TBL] [Abstract][Full Text] [Related]
4. Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival.
Alvarez C; Aravena A; Tapia T; Rozenblum E; Solís L; Corvalán A; Camus M; Alvarez M; Munroe D; Maass A; Carvallo P
BMC Cancer; 2016 Mar; 16():219. PubMed ID: 26979459
[TBL] [Abstract][Full Text] [Related]
5. Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue.
Vilasco M; Communal L; Hugon-Rodin J; Penault-Llorca F; Mourra N; Wu Z; Forgez P; Gompel A;
Breast Cancer Res Treat; 2013 Nov; 142(2):283-96. PubMed ID: 24166279
[TBL] [Abstract][Full Text] [Related]
6. Metabolomics reveals novel blood plasma biomarkers associated to the BRCA1-mutated phenotype of human breast cancer.
Roig B; Rodríguez-Balada M; Samino S; Lam EW; Guaita-Esteruelas S; Gomes AR; Correig X; Borràs J; Yanes O; Gumà J
Sci Rep; 2017 Dec; 7(1):17831. PubMed ID: 29259228
[TBL] [Abstract][Full Text] [Related]
7.
Lips EH; Debipersad RD; Scheerman CE; Mulder L; Sonke GS; van der Kolk LE; Wesseling J; Hogervorst FB; Nederlof PM
Clin Cancer Res; 2017 Mar; 23(5):1236-1241. PubMed ID: 27620280
[No Abstract] [Full Text] [Related]
8. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.
Quinn JE; Kennedy RD; Mullan PB; Gilmore PM; Carty M; Johnston PG; Harkin DP
Cancer Res; 2003 Oct; 63(19):6221-8. PubMed ID: 14559807
[TBL] [Abstract][Full Text] [Related]
9. Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents.
Andres JL; Fan S; Turkel GJ; Wang JA; Twu NF; Yuan RQ; Lamszus K; Goldberg ID; Rosen EM
Oncogene; 1998 Apr; 16(17):2229-41. PubMed ID: 9619832
[TBL] [Abstract][Full Text] [Related]
10. Differing effects of breast cancer 1, early onset (BRCA1) and ataxia-telangiectasia mutated (ATM) mutations on cellular responses to ionizing radiation.
Mamon HJ; Dahlberg W; Azzam EI; Nagasawa H; Muto MG; Little JB
Int J Radiat Biol; 2003 Oct; 79(10):817-29. PubMed ID: 14630541
[TBL] [Abstract][Full Text] [Related]
11. Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents.
Tassone P; Blotta S; Palmieri C; Masciari S; Quaresima B; Montagna M; D'Andrea E; Eramo OP; Migale L; Costanzo F; Tagliaferri P; Venuta S
Int J Oncol; 2005 May; 26(5):1257-63. PubMed ID: 15809716
[TBL] [Abstract][Full Text] [Related]
12. Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers.
Santarosa M; Del Col L; Tonin E; Caragnano A; Viel A; Maestro R
Mol Cancer Ther; 2009 Apr; 8(4):844-54. PubMed ID: 19372557
[TBL] [Abstract][Full Text] [Related]
13. BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Tanino H; Kosaka Y; Nishimiya H; Tanaka Y; Minatani N; Kikuchi M; Shida A; Waraya M; Katoh H; Enomoto T; Sengoku N; Kajita S; Hoffman RM; Watanabe M
PLoS One; 2016; 11(12):e0165721. PubMed ID: 27935989
[TBL] [Abstract][Full Text] [Related]
14. Glucose-regulated protein 78 as a novel effector of BRCA1 for inhibiting stress-induced apoptosis.
Yeung BH; Kwan BW; He QY; Lee AS; Liu J; Wong AS
Oncogene; 2008 Dec; 27(53):6782-9. PubMed ID: 18776923
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.
Takada M; Nagai S; Haruta M; Sugino RP; Tozuka K; Takei H; Ohkubo F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Sato Y; Ogawa S; Kaneko Y
Genes Chromosomes Cancer; 2017 May; 56(5):405-420. PubMed ID: 28124401
[TBL] [Abstract][Full Text] [Related]
16. Egr-1 regulates the transcription of the BRCA1 gene by etoposide.
Shin SY; Kim CG; Lee YH
BMB Rep; 2013 Feb; 46(2):92-6. PubMed ID: 23433111
[TBL] [Abstract][Full Text] [Related]
17. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
18. BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II.
Treszezamsky AD; Kachnic LA; Feng Z; Zhang J; Tokadjian C; Powell SN
Cancer Res; 2007 Aug; 67(15):7078-81. PubMed ID: 17671173
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 and BARD1 colocalize mainly in the cytoplasm of breast cancer tumors, and their isoforms show differential expression.
Wiener D; Gajardo-Meneses P; Ortega-Hernández V; Herrera-Cares C; Díaz S; Fernández W; Cornejo V; Gamboa J; Tapia T; Alvarez C; Carvallo P
Breast Cancer Res Treat; 2015 Oct; 153(3):669-78. PubMed ID: 26395808
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA signatures in hereditary breast cancer.
Murria Estal R; Palanca Suela S; de Juan Jiménez I; Egoavil Rojas C; García-Casado Z; Juan Fita MJ; Sánchez Heras AB; Segura Huerta A; Chirivella González I; Sánchez-Izquierdo D; Llop García M; Barragán González E; Bolufer Gilabert P
Breast Cancer Res Treat; 2013 Nov; 142(1):19-30. PubMed ID: 24129975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
